These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20951178)

  • 1. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay.
    Bussiere JL; Leach MW; Price KD; Mounho BJ; Lightfoot-Dunn R
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):493-502. PubMed ID: 20951178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.
    Leach MW; Halpern WG; Johnson CW; Rojko JL; MacLachlan TK; Chan CM; Galbreath EJ; Ndifor AM; Blanset DL; Polack E; Cavagnaro JA
    Toxicol Pathol; 2010 Dec; 38(7):1138-66. PubMed ID: 20926828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexibility--the guiding principle for antibody manufacturing.
    Carson KL
    Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules - A survey of industry 2008-2019.
    MacLachlan TK; Price S; Cavagnaro J; Andrews L; Blanset D; Cosenza ME; Dempster M; Galbreath E; Giusti AM; Heinz-Taheny KM; Fleurance R; Sutter E; Leach MW
    Regul Toxicol Pharmacol; 2021 Apr; 121():104872. PubMed ID: 33485926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles.
    Muller RH; Keck CM
    J Biotechnol; 2004 Sep; 113(1-3):151-70. PubMed ID: 15380654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target selection and pharma industry productivity: what can we learn from technology S-curve theory?
    Brown D
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):414-8. PubMed ID: 16889225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceuticals: recent approvals and likely directions.
    Walsh G
    Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
    Trosko JE; Chang CC
    Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity.
    Depta JP; Altznauer F; Gamerdinger K; Burkhart C; Weltzien HU; Pichler WJ
    J Allergy Clin Immunol; 2004 Mar; 113(3):519-27. PubMed ID: 15007356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance of the toxicity of pharmaceuticals in humans and in animals.
    Olson H; Betton G; Robinson D; Thomas K; Monro A; Kolaja G; Lilly P; Sanders J; Sipes G; Bracken W; Dorato M; Van Deun K; Smith P; Berger B; Heller A
    Regul Toxicol Pharmacol; 2000 Aug; 32(1):56-67. PubMed ID: 11029269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building biomanufacturing capacity--the chapter and verse.
    Kamarck ME
    Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots.
    Sivakumar G
    Biotechnol J; 2006 Dec; 1(12):1419-27. PubMed ID: 17136730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Society for Biomolecular Sciences--15th Annual Conference. Bioassay and technology innovation: 15 years of shaping drug discovery. 26-30 April 2009, Lille, France.
    Napper AD
    IDrugs; 2009 Jun; 12(6):363-5. PubMed ID: 19517316
    [No Abstract]   [Full Text] [Related]  

  • 18. Discovery and development of biopharmaceuticals: current issues.
    Strohl WR; Knight DM
    Curr Opin Biotechnol; 2009 Dec; 20(6):668-72. PubMed ID: 19896824
    [No Abstract]   [Full Text] [Related]  

  • 19. Biopharma in Piedmont, Italy.
    Sakariassen KS
    Nat Rev Drug Discov; 2005 Jun; 4(6):519. PubMed ID: 15959953
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.